April 4, 2025 05:10 PM EDTUpdated April 4, 10:18 PM
Pharma
FDA+

Trump ad­min­is­tra­tion leaves obe­si­ty cov­er­age ex­pan­sion out of new Medicare rule

Nicole DeFeudis

Editor

The Trump ad­min­is­tra­tion fi­nal­ized new poli­cies for some Medicare pro­grams on Fri­day, but left out pro­vi­sions that would have ex­pand­ed cov­er­age of an­ti-obe­si­ty drugs to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bris­tol My­ers CEO sig­nals deal­mak­ing will be a top pri­or­i­ty in 2025

Drug­mak­ers see a sub­stan­tial, but man­age­able, hit to busi­ness from tar­iffs. But the worst may lie ahead

Roche CEO warns that tar­iffs could im­pact deal­mak­ing

Ver­san­t's lat­est biotech fo­cus­es on in­flam­ma­to­ry dis­eases

Roche takes steps to pro­tect it­self from tar­iffs, while Sanofi hangs back

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times